Company Overview and News

 
Jain Irrigation Systems Limited - Press Release

2018-09-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500219 570004 JISLDVREQS JISLJALEQS

 
Jain Irrigation Systems Limited - Press Release

2018-09-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500219 570004 JISLDVREQS JISLJALEQS

 
Jain Irrigation Systems Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500219 570004 JISLDVREQS JISLJALEQS

 
Jain Irrigation Systems Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500219 570004 JISLDVREQS JISLJALEQS

 
Jain Irrigation Systems Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500219 570004 JISLDVREQS JISLJALEQS

 
Jain Irrigation Systems Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500219 570004 JISLDVREQS JISLJALEQS

 
Check out the top 10 stocks which moved the most last week

2018-09-02 moneycontrol
Equities did not have the best of their starts to a new series, with the Nifty ending the first day of September series below 11,700-mark. However, bulls did manage to battle it out well with the bears as the market was off its low points.
500219 ABBOTINDIA 570004 RELEY RIFS 539254 RELFF 532627 JISLJALEQS TCHQY 532778 532755 TECHM 500390 RELINFRA JISLDVREQS RIFA JPPOWER 500488 LITL ADANITRANS

 
Jain Irrigation Systems Limited - Shareholders meeting

2018-09-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500219 570004 JISLDVREQS JISLJALEQS

 
Jain Irrigation Systems Limited - Shareholders meeting

2018-09-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500219 570004 JISLDVREQS JISLJALEQS

 
Company news: Jain Irrigation Systems

2018-08-29 thehindubusinessline
Jain Irrigation Systems (JISL) on Wednesday announced award of an $18.27-million (about ₹127 crore) contract by Rwanda Agriculture Board (RAB), Kigali, for irrigation (1,220 ha) and watershed development (1,752 ha) in Mahama Sector. The order, which is under Export Targeted Modern Irrigated Agriculture Projects, will be executed near Rusumo (Rwanda-Tanzania border). The project is financed by EXIM Bank of India under the Government of India Line of Credit programme.
500219 570004 500228 JISLDVREQS JISLJALEQS JSWSTEEL

3
Jain Irrigation bags Rs 127 crore contract from Rwanda

2018-08-29 moneycontrol
Jain Irrigation Systems (JISL) today said it has received a contract worth Rs 127 crore ($18.7 million) from the Rwandan government for developing irrigation and watershed facilities.
500219 BRK.A 570004 JISLDVREQS JISLJALEQS

 
Jain Irrigation Systems Limited - Press Release

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500219 570004 JISLDVREQS JISLJALEQS

 
Jain Irrigation Systems Limited - Press Release

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500219 570004 JISLDVREQS JISLJALEQS

 
Jain Irrigation Systems Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500219 570004 JISLDVREQS JISLJALEQS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...